{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:57:14Z","timestamp":1747184234811,"version":"3.40.5"},"reference-count":21,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Background and objectives<\/jats:title><jats:p>Flexible biologic therapy dosing regimens in psoriasis management are common, but data from routine care in Germany are scarce. This study evaluated treatment adjustments for biologic therapies commonly prescribed in Germany.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and methods<\/jats:title><jats:p>Charts for up to 100 consecutive patients treated at 29\u00a0centers were reviewed. Data were extracted for adults (aged 18\u201365\u00a0years) with moderate\u2010to\u2010severe plaque psoriasis treated with adalimumab, guselkumab, ixekizumab, secukinumab, or ustekinumab for \u2265\u00a036\u00a0weeks. The primary endpoint was time to first treatment adjustment. Secondary endpoints included frequency of and reasons for treatment adjustments. Time to treatment adjustment was analyzed using Kaplan\u2010Meier methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 982 patients, 297 treatment adjustments in 240 (24.4%) patients were identified. The mean (median; interquartile range) time to first treatment adjustment (n\u00a0=\u00a0223) was 8.4 (4.0; 2.0\u201312.0) months (secukinumab: 14.1 [10.0; 4.0\u201321.0], adalimumab: 11.0 [7.0; 3.0\u201314.5], ustekinumab: 11.0 [6.0; 2.0\u201316.0], ixekizumab: 5.8 [3.0; 2.0\u20138.5], guselkumab: 5.1 [3.0; 2.0\u20137.0]). The most frequent adjustment type was starting concomitant treatment(s) (10.4% of patients); insufficient skin effectiveness was the most frequent reason for adjustment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Biological treatment adjustments are frequent in moderate\u2010to\u2010severe psoriasis; flexible dosing regimens would support optimal management.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ddg.15448","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T05:25:25Z","timestamp":1722144325000},"page":"1243-1251","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment adjustment in biologic therapies for moderate\u2010to\u2010severe plaque psoriasis: a German retrospective chart review (TABU)"],"prefix":"10.1111","volume":"22","author":[{"given":"Natalia","family":"Kirsten","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE)  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Rubant","sequence":"additional","affiliation":[{"name":"Medical Immunology Department AbbVie Deutschland GmbH &amp; Co. KG  Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Gomis\u2010Kleindienst","sequence":"additional","affiliation":[{"name":"Medical Immunology Department AbbVie Deutschland GmbH &amp; Co. KG  Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Pfeiffer\u2010Vornkahl","sequence":"additional","affiliation":[{"name":"e.factum GmbH  Butzbach Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg\u2010Eppendorf (UKE)  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,7,27]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0265741"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sder.2010.01.002"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3\u2010Guideline on the treatment of psoriasis vulgaris, adapted from EuroGuiDerm \u2013 part 1: treatment goals and treatment recommendations","volume":"19","author":"Nast A","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/ddg.14387","article-title":"Despite large choice of effective therapies: Individuals with psoriasis still seem undertreated","volume":"19","author":"Pilz AC","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11214.x"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033486"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-34293-y"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18981"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1398393"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S167508"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1087-0024.2003.09102.x"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1524820"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2015.1034070"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14145"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475418786712"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2013.768762"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2909"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-00969-8"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T04:29:08Z","timestamp":1744518548000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,27]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1111\/ddg.15448"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15448","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"subject":[],"published":{"date-parts":[[2024,7,27]]},"assertion":[{"value":"2023-08-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}